Recruiting PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT07269041

Immune Tolerance Induction After Liver Transplantation (iTILT)

A Phase I Feasibility Study of HSPC Infusion Following Total Lymphoid Irradiation and Anti-thymocyte Globulin in Patients With a Pre-existing, Well-functioning HLA-matched Living-donor Liver Transplant to Induce Immune Tolerance.

Sponsor: University of California, Los Angeles

Conditions Chimerism End Stage Liver Disease Graft Survival Hematopoietic Stem Cell Immune Tolerance Immune Tolerance/Drug Effects Immunosuppression After Liver Transplantation Immunosuppression Disorders Liver Transplantation

Interventions Donor Hematopoietic Stem and Progenitor Cell Infusion

Updated 3 times since 2026 Last updated: Mar 10, 2026 Started: Feb 20, 2026 Primary completion: Jan 31, 2029 Completion: Jan 31, 2033

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT07269041, this PHASE1/PHASE2 trial focuses on Chimerism and End Stage Liver Disease and remains actively recruiting participants. Sponsored by University of California, Los Angeles, it has been updated 3 times since 2026, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

3 versions recorded

Mar 2026 — Present [monthly]

Recruiting PHASE1/PHASE2

Status: Not Yet Recruiting → Recruiting
Feb 2026 — Mar 2026 [monthly]

Not Yet Recruiting PHASE1/PHASE2
Jan 2026 — Feb 2026 [monthly]

Not Yet Recruiting PHASE1/PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of California, Los Angeles

Data source: University of California, Los Angeles

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Los Angeles, United States